Patents by Inventor Moriteru ASANO

Moriteru ASANO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS
    Publication number: 20230117295
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Heterocyclic compound
    Patent number: 11584737
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
  • Pyrazoloquinazolinone antitumor agents
    Patent number: 11192893
    Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: December 7, 2021
    Assignee: The Rockefeller University
    Inventors: Tarun M. Kapoor, Moriteru Asano, Kazuyoshi Aso, Michael A. Foley, Yoshiyuki Fukase, Hideki Furukawa, Yashuhiro Hirata, Sachie Takashima, Tomohiro Okawa, Yuta Tanaka, Yayoi Yoshitomi
  • HETEROCYCLIC COMPOUND
    Publication number: 20210363130
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: March 28, 2019
    Publication date: November 25, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Heterocyclic amide compound
    Patent number: 10800754
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 13, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Masato Yoshida, Shinichi Imamura
  • Heterocyclic amide compound
    Patent number: 10774083
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 15, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Shinichi Imamura
  • PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS
    Publication number: 20200148687
    Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.
    Type: Application
    Filed: May 18, 2018
    Publication date: May 14, 2020
    Applicant: The Rockefeller University
    Inventors: Tarun M. KAPOOR, Moriteru ASANO, Kazuyoshi ASO, Michael A. FOLEY, Yoshiyuki FUKASE, Hideki FURUKAWA, Yashuhiro HIRATA, Sachie TAKASHIMA, Tomohiro OKAWA, Yuta TANAKA, Yayoi YOSHITOMI
  • HETEROCYCLIC AMIDE COMPOUND
    Publication number: 20190359587
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: September 14, 2017
    Publication date: November 28, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Shinichi IMAMURA
  • HETEROCYCLIC AMIDE COMPOUND
    Publication number: 20190241566
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 8, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Takashi ICHIKAWA, Shinichi IMAMURA
  • Bicyclic compound
    Patent number: 10301292
    Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 28, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Ryo Mizojiri, Hiroshi Banno, Moriteru Asano, Daisuke Tomita, Noriyuki Nii, Hironobu Maezaki, Michiko Tawada
  • Monocyclic compound
    Patent number: 10252997
    Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 9, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Moriteru Asano, Daisuke Tomita, Hiroshi Banno, Michiko Tawada, Noriyuki Nii, Krista E. Gipson, Hironobu Maezaki, Shuntarou Tsuchiya, Mayumi Imai, Yuichiro Amano
  • MONOCYCLIC COMPOUND
    Publication number: 20180079723
    Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.
    Type: Application
    Filed: March 30, 2016
    Publication date: March 22, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Moriteru ASANO, Daisuke TOMITA, Hiroshi BANNO, Michiko TAWADA, Noriyuki NII, Krista E. GIPSON, Hironobu MAEZAKI, Shuntaro TSUCHIYA, Mayumi IMAI, Yuichiro AMANO
  • BICYCLIC COMPOUND
    Publication number: 20180002322
    Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 4, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Hiroshi BANNO, Moriteru ASANO, Daisuke TOMITA, Noriyuki Nii, Hironobu MAEZAKI, Michiko TAWADA